Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2017

Filed with the SEC on Nov 7, 2017 and accepted by EDGAR at Nov 7, 2017, 08:22 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2017-07-01 to 2017-09-30$21.9mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2017-01-01 to 2017-09-30$72.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-07-01 to 2017-09-30−$32.0mus-gaap:OperatingIncomeLoss
Operating income9 months2017-01-01 to 2017-09-30−$96.0mus-gaap:OperatingIncomeLoss
Income tax3 months2017-07-01 to 2017-09-30−$5.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2017-01-01 to 2017-09-30−$5.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2017-07-01 to 2017-09-30−$26.4mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income9 months2017-01-01 to 2017-09-30−$89.2mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2017-07-01 to 2017-09-30−$0.20us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2017-01-01 to 2017-09-30−$0.71us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2017-01-01 to 2017-09-30−$80.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2017-01-01 to 2017-09-30$1.6mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-09-30$54.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-09-30$147.3mus-gaap:AssetsCurrent
Total assetsAt period end2017-09-30$319.4mus-gaap:Assets
Current liabilitiesAt period end2017-09-30$24.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-09-30$100.3mus-gaap:Liabilities
Shareholders' equityAt period end2017-09-30$219.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-17-066472. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.